PCMT1

Across TCGA pan-cancer cohorts, PCMT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCMT1 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PCMT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PCMT1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where PCMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	1.000	0.603	.022	9	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	5	view →
LSCC	DFS	Median	All	0.929	0.615	.025	2	view →
HNSC	DFS	Tertile	III,IV	1.000	0.915	.042	2	view →
PDAC	DFS	Median	All	0.465	0.342	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCMT1–LUAD (DFS)

Open the LUAD breakdown →